Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells.
A high incidence (39%) of positive direct antiglobulin tests (DATs) has been reported in patients taking Unasyn [ampicillin sodium plus sulbactam sodium (a beta-lactamase inhibitor)]. Three of four patients, with positive DATs, receiving Unasyn or Timentin [ticarcillin disodium plus clavulanate potassium (also a beta-lactamase inhibitor)] developed a haemolytic anaemia (HA) associated with a positive DAT, which resolved when drug therapy was stopped. The patients' sera did not react with red blood cells (RBCs) in the presence of Unasyn or Timentin, but when drug-treated RBCs were tested, patients' sera and normal sera reacted equally by indirect antiglobulin test. Following incubation in normal sera, RBCs treated with Unasyn, Timentin, Augmentin (amoxicillin + clavulanate), sulbactam and clavulanate reacted with anti-human globulin and anti-human albumin (an index of non-specific adsorption); RBCs treated with ampicillin and amoxicillin were nonreactive. The beta-lactamase inhibitors sulbactam and clavulanate seem to cause nonimmunologic adsorption of protein onto RBCs in vitro. This may explain the high incidence of positive DATs detected in patients taking Unasyn, which contains sulbactam. It was not possible to prove that there was a direct association between the nonspecific uptake of protein onto drug-treated RBCs in vitro with the positive DATs or the HA.
Garratty
G
G
Immunohematology Research Department, American Red Cross Blood Services, Southern California Region, Los Angeles 90006, USA.
Arndt
P A
PA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000667:Ampicillin / Q000009:adverse effects; D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000276:immunology*; D002969:Clavulanic Acids / Q000009:adverse effects; D003298:Coombs Test; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000378:metabolism; D013407:Sulbactam / Q000009:adverse effects; D013982:Ticarcillin / Q000009:adverse effects
D002969:Clavulanic Acids; D004791:Enzyme Inhibitors; D011506:Proteins; C035444:sultamicillin; D000667:Ampicillin; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin; D013407:Sulbactam